Timing of treatment-switch to telitacicept in high-risk IgA nephropathy: an observational case series of two clinical scenarios - PubMed
6 hours ago
- #Treatment switching
- #Telitacicept
- #IgA nephropathy
- Telitacicept is a BLyS/APRIL inhibitor used in high-risk IgA nephropathy patients for treatment-switching.
- Two clinical scenarios are presented in the case series, focusing on the optimal timing for switching to telitacicept.
- Study approved by ethics board with patient consent, and authors declared no competing interests.